{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T05:46:22Z","timestamp":1776577582525,"version":"3.51.2"},"reference-count":25,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.urolonc.2026.111039","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T19:56:46Z","timestamp":1772135806000},"page":"111039","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combined and individual effects of neoadjuvant chemotherapy and lymph node dissection on survival in non\u2013muscle-invasive bladder cancer undergoing radical cystectomy"],"prefix":"10.1016","volume":"44","author":[{"given":"Yiyu","family":"Sheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Longlong","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sikun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiran","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiqiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyun","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2026.111039_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2026.111039_bib0002","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"10.1016\/j.urolonc.2026.111039_bib0003","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/s41585-025-01072-0","article-title":"Low-grade non-muscle-invasive bladder cancer: molecular landscape, treatment strategies and emerging therapies","volume":"22","author":"Wen","year":"2025","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urolonc.2026.111039_bib0004","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","article-title":"European Association of Urology Guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2025 Guidelines","volume":"87","author":"van der Heijden","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.111039_bib0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/JU.0000000000003981","article-title":"Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/SUO guideline (2017; Amended 2020, 2024)","volume":"212","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.111039_bib0006","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European Association of Urology (EAU) Prognostic Factor Risk Groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC Guidelines Panel","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.111039_bib0007","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","article-title":"European Association of Urology Guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)\u2014a summary of the 2024 guidelines update","volume":"86","author":"Gontero","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.111039_bib0008","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JU.0000000000003846","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.111039_bib0009","article-title":"Effect of neoadjuvant chemotherapy on survival in patients with T1 high-grade non-muscle-invasive bladder cancer who underwent radical cystectomy","volume":"102","author":"Huang","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.urolonc.2026.111039_bib0010","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1392062","article-title":"Neoadjuvant chemotherapy prior to radical cystectomy for non-muscle invasive bladder cancer: national trends and pathologic outcomes","volume":"14","author":"Davis","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.urolonc.2026.111039_bib0011","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/JU.0000000000002266","article-title":"Role of lymphadenectomy during radical cystectomy for nonmuscle-invasive bladder cancer: results from a multi-institutional experience","volume":"207","author":"Khanna","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.111039_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2020.04.027","article-title":"Predictors of adequate lymph node dissection in patients with non-muscle invasive bladder cancer undergoing radical cystectomy and effect on survival","volume":"38","author":"Lenis","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.111039_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fsurg.2022.961430","article-title":"Contemporary use trends and effect on survival of pelvic lymph node dissection for non-muscle-invasive bladder cancer","volume":"9","author":"Tang","year":"2022","journal-title":"Front Surg"},{"key":"10.1016\/j.urolonc.2026.111039_bib0014","unstructured":"Number of persons by race and Hispanic ethnicity for SEER participants. Available from: https:\/\/seer.cancer.gov\/registries\/data.html (Accessed on September 30, 2025)."},{"key":"10.1016\/j.urolonc.2026.111039_bib0015","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence\u2014SEER Research Data, 17 Registries, Nov 2023 Sub (2000\u20132021)\u2014Linked to County Attributes\u2014Time Dependent (1990\u20132022) Income\/Rurality, 1969\u20132022 Counties. National Cancer Institute, DCCPS, Surveillance Research Program; released April 2025. Available at: https:\/\/www.seer.cancer.gov."},{"key":"10.1016\/j.urolonc.2026.111039_bib0016","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2026.111039_bib0017","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2010.32.3139","article-title":"International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial","volume":"29","author":"Griffiths","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.111039_bib0018","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1093\/annonc\/mdu126","volume":"25","author":"Kitamura","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2026.111039_bib0019","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3390\/medicina57050415","article-title":"The usefulness of lymphadenectomy in bladder cancer-current status","volume":"57","author":"Ma\u0142kiewicz","year":"2021","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.urolonc.2026.111039_bib0020","doi-asserted-by":"crossref","first-page":"5286","DOI":"10.3390\/cancers14215286","article-title":"Management of bladder cancer patients with clinical evidence of lymph node invasion (cN+)","volume":"14","author":"Ma\u0142kiewicz","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.urolonc.2026.111039_bib0021","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41585-023-00842-y","article-title":"Management of patients with muscle-invasive bladder cancer with clinical evidence of pelvic lymph node metastases","volume":"21","author":"Grobet-Jeandin","year":"2024","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urolonc.2026.111039_bib0022","doi-asserted-by":"crossref","first-page":"24.e13","DOI":"10.1016\/j.urolonc.2012.08.015","article-title":"Incidence and location of lymph node metastases in patients undergoing radical cystectomy for clinical non-muscle invasive bladder cancer: results from a prospective lymph node mapping study","volume":"32","author":"Bruins","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.111039_bib0023","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/j.1464-410X.2012.10939.x","article-title":"Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome","volume":"110","author":"Turker","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2026.111039_bib0024","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.eururo.2009.09.024","article-title":"Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort","volume":"57","author":"Fritsche","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.111039_bib0025","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1111\/j.1464-410X.2011.10482.x","article-title":"Stage-specific impact of pelvic lymph node dissection on survival in patients with non-metastatic bladder cancer treated with radical cystectomy","volume":"109","author":"Abdollah","year":"2012","journal-title":"BJU Int"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926000505?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926000505?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T05:17:12Z","timestamp":1776575832000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926000505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1078143926000505"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.111039","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined and individual effects of neoadjuvant chemotherapy and lymph node dissection on survival in non\u2013muscle-invasive bladder cancer undergoing radical cystectomy","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.111039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111039"}}